Neurotech Pharmaceuticals, Inc. Granted Fast Track Designation from the U.S. FDA for the Treatment of Macular Telangiectasia type 2
Neurotech Announces Publication of NT-501 Phase 2 Results.
Neurotech Announces Positive Phase 2 Results in NT-501 (CNTF) for Macular Telangiectasia.
Neurotech Announces Renewed Focus on NT-501 (CNTF) Encapsulated Cell Therapy Clinical Programs.
Neurotech Announces First Patient Enrolled in Novel Anti VEGF Encapsulated Cell Therapy Study.
Sustained Release Technology - EuroTimes, May 2015
Neurotech Announces FDA Acceptance of Investigational New Drug Application and Clinical Trial Initiation of Novel Therapy for Wet AMD.
Neurotech Announces Appointment of Dr. Charles Johnson as Chief Medical Officer.
Quinton Oswald Appointed Chief Executive Officer of Neurotech Pharmaceuticals.
Neurotech Pharmaceuticals Adds Ophthalmic Leaders to Advance Groundbreaking Sight-Saving Therapies.
James Mazzo Appointed Executive Chairman of Neurotech Pharmaceuticals.
Two-Year Intraocular Delivery of Ciliary Neurotrophic Factor by Encapsulated Cell Technology Implants in Patients with Chronic Retinal Degenerative Diseases by Kauper et al.
Neurotech Pharmaceuticals relocates to 900 Highland Corporate Drive, Cumberland, Rhode Island
The FDA Orphan Product Division has awarded a grant ($1,459,330 – NIH R01 FD004100-01A1) to fund the study of NT-501 for RP using cone preservation as the endpoint (Jacque Duncan- University of Califo
NT-501 granted orphan-drug designation for macular telangiectasia type 2 (MacTel).